Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial lipooligosaccharides (LOS) are essential glycolipid components of the outer membrane of Gram-negative respiratory pathogens, specifically Moraxella catarrhalis and nontypeable Haemophilus influenzae (NTHi). Unlike the lipopolysaccharides (LPS) found in many enteric bacteria, LOS molecules lack the repeating O-antigen subunits, consisting instead of a conserved Lipid A anchor, a 2-keto-3-deoxy-octulosonic acid (Kdo) core, and a variable, branched oligosaccharide (Apicella, 2012; Murphy, 2015). These molecules serve as critical virulence factors that facilitate bacterial adherence to human respiratory epithelial cells, promote the formation of biofilms, and enable the bacteria to evade the host complement system through the recruitment of regulatory proteins like C4b-binding protein (Schultz et al., 2020). LOS also acts as a potent trigger for the innate immune system by activating the Toll-like receptor 4 (TLR4) complex, which drives the localized inflammatory response characteristic of otitis media and chronic obstructive pulmonary disease (COPD) exacerbations (Tan et al., 2005). Because of their prominent surface exposure and essential role in pathogenesis, LOS structures are primary targets for the development of conjugate vaccines and therapeutic monoclonal antibodies designed to elicit protective bactericidal immunity and prevent colonization (Yu et al., 2018). However, therapeutic development must address the inherent endotoxicity of the Lipid A component and the potential for molecular mimicry, where bacterial oligosaccharides resemble human glycosphingolipids to avoid immune detection.
Induction of opsonophagocytic and bactericidal antibodies; neutralization of Lipid A-mediated TLR4 signaling; inhibition of bacterial colonization and adherence to host respiratory epithelia.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial lipooligosaccharide (LOS) antigens from Moraxella catarrhalis and nontypeable Haemophilus influenzae (LOS).